Results 91 to 100 of about 6,214,933 (159)

Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa

open access: yesMolecular Genetics and Metabolism Reports
Introduction: Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), is a neurodegenerative autosomal recessive disease caused by TPP1 gene variants, with a spectrum of classic and atypical phenotypes.
Norberto Guelbert   +34 more
doaj   +1 more source

Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment

open access: yes, 2021
Classic late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is caused by a deficiency of tripeptidyl-peptidase-1. In 2017, the first CLN2 enzyme replacement therapy (ERT) cerliponase alfa (Brineura) was approved by the FDA and EMA.
Mills, Philippa B   +11 more
core  

Lysosomal serine protease CLN2 regulates tumor necrosis factor-alpha-mediated apoptosis in a Bid-dependent manner.

open access: yes, 2009
International audienceApoptosis is a highly organized, energy-dependent program by which multicellular organisms eliminate damaged, superfluous, and potentially harmful cells.
Marie-Laure Nicolau   +19 more
core   +1 more source

Analysis of CLN1 and CLN2 expression in the cln3 bck2 stb1 and cln3 bck2 whi5 strains.

open access: yes, 2013
qPCR was used to measure the expression of CLN1 and CLN2 in two of the suppressor strains. The parental strain is cln3 bck2 rme1 {MET-CLN2} (N497), and the two suppressor strains have, in addition, stb1 (N451) or whi5 (N499), as indicated.
Herman Wijnen (61991)   +4 more
core   +1 more source

First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy

open access: yes, 2023
BACKGROUND/OBJECTIVES: CLN2 Batten Disease is a fatal neurodegenerative condition of childhood associated with retinal dystrophy and blindness. Intracerebroventricular infusion of rhTPP1 greatly slows the rate of neurodegenerative decline but not ...
Gan, Chin   +11 more
core  

Karyopherin Msn5 is involved in a novel mechanism controlling the cellular level of cell cycle regulators Cln2 and Swi5

open access: yes, 2019
The yeast β-karyopherin Msn5 controls the SBF cell-cycle transcription factor, responsible for the periodic expression of CLN2 cyclin gene at G1/S, and the nuclear export of Cln2 protein.
Inma Quilis (4351246)   +4 more
core   +1 more source

Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients. [PDF]

open access: yesJ Child Neurol, 2021
Schwering C   +8 more
europepmc   +1 more source

Intrathecal enzyme replacement therapy for CLN2 disease [PDF]

open access: yesCellular Therapy and Transplantation, 2019
openaire   +1 more source

Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness – A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 Disease

open access: yesEye and Brain
Nikolaos Gkalapis,1,2,* Simon Dulz,1,* Carsten Grohmann,1 Miriam Nickel,3 Christoph Schwering,3 Eva Wibbeler,3 Martin Stephan Spitzer,1 Angela Schulz,3 Yevgeniya Atiskova1 1Department of Ophthalmology, University Medical Center Hamburg-Eppendorf,
Gkalapis N   +8 more
doaj  

Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness - A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 Disease. [PDF]

open access: yesEye Brain
Gkalapis N   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy